Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF (MSP-IVC)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study to evaluate a low cost minimal stimulation protocol combined with Intravaginal Culturing, to make IVF affordable and available across the large infertile/subfertile population
| Condition | Intervention |
|---|---|
|
Primary Infertility Secondary Infertility Low Responders Mild to Moderate Male Factor Infertility |
Drug: Letrozole 2.5 mg, recFSH 75 IU Procedure: STEP-3: LH Suppression & Monitoring Procedure: STEP-4: HCG Timing Procedure: STEP-5: OPU, ET, Cancellation Procedure: INVOCell (Intravaginal Culturing) |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | A Scientific & Clinical Review of Minimal Stimulation Protocol Using AROMEK (Letrozole) and Follitrope (Recombinant FSH)Combined With INVOCell(Intravaginal Culturing) - Effectiveness as Low Cost IVF |
- Number of Follicles >15 mm on the day of HCG; Number of Oocytes aspirated; Fertilisation Rate [ Time Frame: Quarterly ] [ Designated as safety issue: Yes ]
- Pregnancy Rate; Cost of Treatment [ Time Frame: Every 6 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 100 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | February 2012 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Letrozole, recFSH, IVC, Monitoring
Infertile couple following MSP with IVC
|
Drug: Letrozole 2.5 mg, recFSH 75 IU
OVARIAN STIMULATION: In previous cycles, cycle length and ovulatory status must be assessed and documented. STEP 1: ANOVULATION by ORAL CONTRACEPTION
STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).
Other Names:
Procedure: STEP-3: LH Suppression & Monitoring
Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle. • When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation. The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2) No need of LH testing, or E2 testsing during the stimulated cycle. IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:
Other Name: IVF-C 5000 IU
Procedure: STEP-5: OPU, ET, Cancellation
Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection. Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage. Maximum of 2 embryos are transferred, using ultrasound guided transfer. Cancellation Criteria:
Other Names:
Procedure: INVOCell (Intravaginal Culturing)
Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 30000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
Other Names:
|
Detailed Description:
In routine ART procedures for IVF, ovarian stimulation is performed using down regulation with GNRH Agonist combined with high daily FSH doses followed with ovulation induction with HCG 10000 IU, ovum pick-up 34-36 hours after HCG injection and embryo transfer on day 2, 3 or 5.
In routine ART procedure for IVF, embryology is done in very high tech lab, contamination free environment, which also exclude VOC, high quality CO2 Incubators, laminar flow with heated table top, high magnification stereo microscope along with equipments for maintaining quality control, with a highly trained embryologist. The primary reason is we need to create a womb like environment in the embryology lab as eggs, and mainly fertilised embryos are going to spend minimum 2 or 3 and in case blastocyst 5 days in this lab.
In recent years, various studies have been published identifying various minimal stimulation protocols for IVF, and also another variation of IVF where rather than using CO2 Incubator for culturing, vaginal cavity of the female partner is used for incubation using a specially designed capsule which have walls permeable to vaginal pCO2 and O2. Oocytes are retrieved by the physician and handed over to basic embryologist to identify and grade oocytes and washed sperms are placed in a embryo toxic tested, sterile, individual single use capsule (INVOCell) and placed in vaginal cavity using diaphragm, patient goes back to home with some instructions for care, on day 2 patient comes back to the IVF Clinic and physician gets the capsule out and hands over to the basic embryologist trained on INVOCell to identify embryos and grade them, further loading of embryos on ET Catheter.
Eligibility| Ages Eligible for Study: | 20 Years to 37 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
IVF Network Centers across the country, selecting patients meeting inclusion criteria.
Inclusion Criteria:
- Tubal factor without Hydrosalpinx
- Unexplained infertility with unsuccessful attempts in achieving pregnancy through timed intercourse or IUI
- Boarder line male factor infertility
- Sperm DNA Fragmentation < 30%
- Normal Uterine Cavity
- Normal baseline ultrasound with adequate number of primary follicles present
- Normal FSH and E2 on Day 3
- Age of the female is < 35 years old
Exclusion Criteria:
- If previous IVF or INVO attempts resulted in failed fertilisation
- Male partner who has difficulty in producing semen sample
- Very low sperm count, very low percentage of sperm motility and morphology
- Sperm DNA Fragmentation > 30%
- Age of female patient > 37 years
- Borderline or elevated E2 or FSH on day 3 or failed CCCT or low blood inhibin levels
- Poor ovarian response
- Hydrosalpinx
- Anatomic difficulties in reaching ovaries for oocyte retrieval
- Cervical stenosis, making embryo transfer difficult
- Uterine abnormalities or deformities
- Obesity
Contacts and Locations| Contact: Prof. Claude Ranoux, MD | 978 878-9505 | clauderanoux@invobioscience.com |
| Contact: Saif Ur Rehman | 0092 323 2440710 | saifrehman@galaxyivf.com |
| Pakistan | |
| Friends Ivf | Recruiting |
| Faisalabad, Punjab, Pakistan | |
| Contact: Dr. Samina Khalid, MCPS, FCPS 0092 300 8664227 | |
| Sub-Investigator: Dr. Samina Khalid, MCPS, FCPS | |
| Fertility Care Multan | Recruiting |
| Multan, Punjab, Pakistan | |
| Contact: Prof. Samee Akhtar 0092 300 8637070 | |
| Principal Investigator: Prof. Samee Akhtar, FCPS, FRCOG | |
| Sub-Investigator: Talha Mabood Paracha, Embryologyst | |
| Galaxy IVF Limited | Recruiting |
| Karachi, Sindh, Pakistan, 75300 | |
| Contact: Saif Ur Rehman 0092 323 2440710 saifrehman@galaxyivf.com | |
| Contact: Talha Mabood Paracha, Embryologyst | |
| Sub-Investigator: Talha Mabood Paracha, Embryologyst | |
| American IVF & Pregnancy Center | Recruiting |
| Karachi, Sindh, Pakistan | |
| Contact: Dr. Asma Munir, MCPS, FCPS | |
| Contact: Pervaiz Masood Khan | |
| Principal Investigator: Prof. Claude Ranoux, MS, MD | |
| Study Chair: | Prof. Claude Ranoux, MD | INVOBioscience, USA |
More Information
Publications:
| Responsible Party: | Saif Ur Rehman, Project Director, Galaxy IVF (UK) Limited |
| ClinicalTrials.gov Identifier: | NCT01058252 History of Changes |
| Other Study ID Numbers: | GIVF-1001 |
| Study First Received: | January 27, 2010 |
| Last Updated: | February 6, 2011 |
| Health Authority: | Pakistan: Research Ethics Committee |
Additional relevant MeSH terms:
|
Infertility Genital Diseases, Male Genital Diseases, Female Chorionic Gonadotropin Indomethacin Letrozole Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses Gout Suppressants Antirheumatic Agents Tocolytic Agents |
Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Anti-Inflammatory Agents Cardiovascular Agents Central Nervous System Agents Antineoplastic Agents Aromatase Inhibitors |
ClinicalTrials.gov processed this record on May 23, 2013